Skip to Main Content

Cambridge biotech Tango Therapeutics is going public through a $353 million deal with a special purpose acquisition company, the precision cancer medicine firm announced on Wednesday.

The SPAC, called BCTG Acquisition Corp., is backed by Boxer Capital, one of the biotech’s investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!